Peregrine Pharmaceuticals (NASDAQ:PPHM) will report second quarter results after the bell today, and given that shares have done little this year, investors are right to be looking for clues as to when the company's promising immunotherapy drug for cancer may make an impact.

PPHM Chart

PPHM data by YCharts

In the following slideshow, I offer insight into Peregrine's bavituximab and outline key questions I'll be looking to have answered during the second quarter conference call.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.